Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile - Fierce Biotech

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in anothe | As Eli Lilly looks to hold its lead in the lucrative obesity market, …